CRVS Stock Corvus Pharmaceuticals (CRVS, $8.05) price may drop as it broke higher Bollinger Band on Jan 16, 2026

GET DAILY SIGNALS

Get AI intraday signals

CRVS - Corvus Pharmaceuticals

Bollinger signal

View

Odds of DOWN Trend

Price: $8.05

Daily change: +$0.91 (+12.75%)

Daily volume: 3.1M

Capitalization: $601.2M

Industry: Biotechnology

This price move could be a signal that CRVS may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 53 similar cases where CRVS's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:

CRVS in -4.27% downward trend, sliding for three consecutive days on January 13, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CRVS declined for three days, in of 302 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for CRVS crossed bearishly below the 50-day moving average on December 23, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

CRVS broke above its upper Bollinger Band on January 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CRVS entered a downward trend on January 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRVS's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where CRVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 16, 2026. You may want to consider a long position or call options on CRVS as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CRVS just turned positive on January 16, 2026. Looking at past instances where CRVS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

CRVS moved above its 50-day moving average on January 16, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.375) is normal, around the industry mean (27.905). P/E Ratio (0.000) is within average values for comparable stocks, (51.163). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (324.226).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.